Mostrar Noticias:

BMYPrincipalesÚltima Hora

 Ver noticias de otros activos

Búsqueda de noticias relacionadas a la acción Bristol-Myers Squ (ordenadas por fecha):

Institutional Trading Activity Report for Bristol-Myers Squibb Company (BMY) AVAFIN Bristol-Myers Squibb Company is trading below the 50 day moving average and higher than the 200 day moving average. Shares of BMY opened today at $32.68 and settled the day up $0.12 to $32.83 during the session. The day's trading range is between ...

The Zacks Analyst Blog Highlights: Mylan, Bristol-Myers Squibb, Sanofi, Teva ... Sacramento Bee Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Mylan, Inc. (Nasdaq:MYL), Bristol-Myers Squibb Co. (NYSE:BMY), Sanofi (NYSE:SNY), ... Generic Launches Continue At MylanDaily Markets los 23 artículos informativos »

Bristol-Myers Squibb's Thud Heard Round the World DailyFinance By Sean Williams, The Motley Fool It was only a matter of time before Plavix, Bristol-Myers Squibb's (NYS: BMY) best-selling blood-clot-fighting drug, was set to lose patent protection. Well, folks, that day has come and gone as of last Thursday, ... BMO Capital Markets Analysts Begin Coverage on Bristol Myers Squibb (BMY)Movie News Guide (blog) Generic Launches Continue at Mylan - AnalystBlog - In SpotlightThe Mumbai Times los 6 artículos informativos »

Dividend.com

Our Take: Bristol Myers Squibb Started as ?Outperform? at BMO Capital (BMY) The Mumbai Times Pharmaceuticals giant Bristol Myers Squibb Co. (BMY) on Friday caught some bullish commentary from analysts at BMO Capital. The firm initiated coverage on BMY with an ?Outperform? rating and $39 price target, which suggests a 19% upside to the stock's ... Bristol-Myers anticipates significant decline in US clopidogrel sales as ...The Pharma Letter Bristol-Myers starts Orencia manufacturing at new plantFiercePharma Manufacturing Bristol-Myers (BMY) Announces FDA Approval of Devens, MA Plant for Manufacture ...StreetInsider.com (subscription) EON: Enhanced Online News (press release) -AVAFIN -MedCity News los 24 artículos informativos »

Asian Scientist Magazine

Manufacturing Facility Cleared at BMY Zacks.com Bristol-Myers Squibb Company (BMY - Analyst Report) received some encouraging news when the US Food and Drug Administration (FDA) cleared a biologics manufacturing facility of the company for producing its rheumatoid arthritis (RA) drug, Orencia. Bristol-Myers Squibb and Tsinghua University Enter Strategic PartnershipMarketWatch (press release) Bristol-Myers Squibb to Present New Data on ORENCIA(R) (abatacept) at the ...Sacramento Bee Bristol-Myers Squibb to Present New Data on ORENCIA® (abatacept) at the ...SunHerald.com los 97 artículos informativos »

The Zacks Analyst Blog Highlights: Dr. Reddy's Laboratories, Bristol-Myers ... Zacks.com Stocks recently featured in the blog include Dr. Reddy's Laboratories (RDY - Snapshot Report), Bristol-Myers Squibb & Co. (BMY - Analyst Report), Teva Pharmaceutical Industries Ltd. (TEVA - Analyst Report), Biogen Idec (BIIB - Analyst Report) and Elan ... y más »

U.S. News & World Report

New Data from Bristol-Myers Squibb Oncology Portfolio to be Presented at 2012 ... MarketWatch (press release) Bristol-Myers Squibb Company (NYSE:BMY) today announced that new data on its approved and investigational oncology compounds will be featured in ten oral presentations at the 48th Annual Meeting of the American Society of Clinical Oncology (ASCO) in ... Drug Makers Continue Shift To Targeted Cancer TherapiesWall Street Journal ASCO '12 Abstract Dump: Cancer Stocks in FocusTheStreet.com Highlights of presentations planned for ASCO meetingThe Pharma Letter los 126 artículos informativos »

The Zacks Analyst Blog Highlights: Dr. Reddy's Laboratories, Bristol-Myers ... Sacramento Bee Stocks recently featured in the blog include Dr. Reddy's Laboratories (NYSE:RDY), Bristol-Myers Squibb & Co. (NYSE:BMY), Teva Pharmaceutical Industries Ltd. (Nasdaq:TEVA), Biogen Idec (Nasdaq:BIIB) and Elan Corporation, plc (NYSE:ELN). y más »

The Zacks Analyst Blog Highlights: Dr. Reddy's Laboratories, Bristol-Myers ... PR Newswire (press release) Stocks recently featured in the blog include Dr. Reddy's Laboratories (NYSE: RDY), Bristol-Myers Squibb & Co. (NYSE: BMY), Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA), Biogen Idec (Nasdaq: BIIB) and Elan Corporation, plc (NYSE: ELN). y más »

Lilly, Jaguar Land Rover, Viacom: Intellectual Property BusinessWeek (LLY) (LLY) and AstraZeneca Plc (AZN) won't have an easier time gaining more of the market for blood thinners dominated by Bristol-Myers Squibb Co. (BMY) (BMY)'s Plavix after the drug lost US patent protection yesterday. Plavix Patent Loss Doesn't Mean Gain by Competing Blood ThinnersBloomberg los 4 artículos informativos »

Lilly, Jaguar Land Rover, Viacom: Intellectual Property Bloomberg (LLY) and AstraZeneca Plc (AZN) won't have an easier time gaining more of the market for blood thinners dominated by Bristol-Myers Squibb Co. (BMY)'s Plavix after the drug lost US patent protection yesterday. Lilly's Effient and AstraZeneca's Brilinta ... y más »

Dividend.com

Bristol-Myers Profit Climbs, Backs Forecast NASDAQ (RTTNews.com) - Bristol-Myers Squibb Co. (BMY) reported Thursday a 12 percent increase in first-quarter profit, above Street estimates, boosted by higher sales, even as its blockbuster drug Plavix recorded lower sales. The Biopharmaceutical firm also ... Bristol Myers Squibb Co (NYSE:BMY) Meets Analysts Forecasts; investors Focus ...PT News Bristol Myers Squibb Co. (NYSE:BMY) Shares Down As Revenue Misses ForecastU.S. Election News Bristol-Myers Squibb Invites Public To Listen To Webcast Of 2012 Annual MeetingTheStreet.com (press release) DailyFinance -The Pharma Letter los 95 artículos informativos »

Pfizer (NYSE:PFE) Cancers Drug Xalkori Stops Deadly Kids Tumor ?PFE, MRK, ABT ... The Mumbai Times Merck & Co., Inc. (NYSE:MRK) decreased -0.55% to settle at $37.82, Abbott Laboratories (NYSE:ABT) fell -1.06% to end at $61.57 while Bristol Myers Squibb Co. (NYSE:BMY) moved down -0.09% to finish on Friday at $32.72. Pfizer Inc. (NYSE:PFE) began the ... Healthcare Giant Pfizer (NYSE:PFE) Recalls 650000 Units of Advil Liqui-Gels ...eStocksDaily Pfizer Inc. (NYSE:PFE) Engages Distributors To Recall Advil Liqui-Gels From StoresU.S. Election News los 5 artículos informativos »

Stocks Reaching Trendline Support (Bullish) onMay-21 - Breaking News The Mumbai Times Bristol-Myers Squibb Company (NYSE:BMY) is currently trading at $32.72. BMY is trading -1.46% below its 50 day moving average and 3.43% above its 200 day moving average. BMY is -6.51% below its 52-week high and 31.24% above its 52-week low. y más »

Bristol-Myers Squibb To Present At Bank Of America Merrill Lynch Health Care ... TheStreet.com (press release) By Business Wire 05/10/12 - 11:00 AM EDT Bristol-Myers Squibb Company (NYSE: BMY) will present at Bank of America Merrill Lynch Health Care Conference on Thursday, May 17, 2012 in Las Vegas. Doug Manion, senior vice president, Development, Neuroscience ... y más »

Did You Buy These Stocks? NASDAQ In March, Amylin rejected a $3.5 billion unsolicited takeover offer from Bristol-Myers Squibb Co. (BMY). Omeros Corp. (OMER) is a biopharmaceutical company focused on developing products for inflammation, bleeding and disorders of the central nervous ... y más »

CBS News

FDA Approves Generic Versions Of Blood-Thinning Drug Plavix NASDAQ Plavix, marketed by Bristol-Myers Squibb Co. (BMY) and Sanofi (SNY), is used to ward off heart attacks and strokes in people with cardiovascular disease, and was among the best-selling drugs in history. The drug's $6.8 billion in US sales last year, ... Dr. Reddy's Launches Plavix' GenericZacks.com Generic floodgates open for Plavix in USFiercePharma US FDA approves generic versions of blood thinner PlavixThe Pharma Letter RTT News -Investorplace.com los 292 artículos informativos »

WWLP 22News

J&J-Bayer Xarelto's Use in Prevention Is Effective, FDA Says BusinessWeek The drug would be taken twice daily in combination with aspirin and Plavix, made by Paris-based Sanofi (SAN) and New York-based Bristol-Myers Squibb Co. (BMY) (BMY) Xarelto is one of the medicines attempting to replace warfarin, which requires constant ... Johnson & Johnson's Xarelto Should Be Given to More Patients, FDA Staff SaysMinyanville.com FDA Reviewer Backs Expanded Approval Of Bayer, J&J's XareltoFox Business FDA review backs Xarelto for big new use in ACS patientsFiercePharma FierceBiotech los 179 artículos informativos »

Bloomberg

Amylin Said to Attract Interest From Pfizer, AstraZeneca BusinessWeek (4502), Roche Holding AG (ROG) and Bristol-Myers Squibb Co. (BMY) (BMY) also signed agreements to get access to confidential financial and product information for Amylin, said the people, who declined to be identified as talks are private. This Biotech's for Sale! Reportedly.DailyFinance Amylin (AMLN) Attracting a Host of Other Suitors, Shares RiseStreetInsider.com (subscription) los 10 artículos informativos »

Stocks Reaching Trendline Support (Bullish) on May-21 - In Spotlight The Mumbai Times Bristol-Myers Squibb Company (NYSE:BMY) is currently trading at $32.72. BMY is trading -1.46% below its 50 day moving average and 3.43% above its 200 day moving average. BMY is -6.51% below its 52-week high and 31.24% above its 52-week low.

Our Take: Our Take: Stock Analysts' New Coverage for May, 18th (ACOR, ANGI ... The Mumbai Times They set a ?sell? rating on the stock. Angie's List (NASDAQ: ANGI) is now covered by analysts at Raymond James. They set an ?outperform? rating on the stock. Bristol Myers Squibb Co. (NYSE: BMY) is now covered by analysts at BMO Capital Markets. y más »

Forbes

Our Take: Earnings Scorecard: Bristol-Myers The Mumbai Times Bristol-Myers Squibb Co (NYSE:BMY) shares were trading at $33.37 while reporting down 0.39% from yesterdays close. The 17 analysts offering 12-month price forecasts for Bristol-Myers Squibb Co have a median target of 34.00, with a high estimate of ... Earnings Scorecard: Bristol-Myers - Analyst BlogNASDAQ los 96 artículos informativos »

8 High-Dividend, Large-Cap Stocks With Little Debt Seeking Alpha The above table shows the trailing P/E ratios. Bristol-Myers Squibb (BMY) is a biopharmaceutical company operating worldwide. BMY recently traded at $32.72 and has a 4.2% dividend yield. BMY gained 19.2% during the past 12 months. y más »

TheStreet.com

Bristol-Myers Missing Hep C Data Raises Red Flags, May Boost Gilead, Idenix TheStreet.com ... 07:00 AM EDT NEW YORK (TheStreet) -- Since my return from the European Association for the Study of the Liver (EASL) conference two weeks ago, I have been unable to get over the strange behavior of executives at Bristol-Myers Squibb(BMY).

Bristol-Myers Squibb To Present At Deutsche Bank Health Care Conference TheStreet.com (press release) By Business Wire 04/30/12 - 01:20 PM EDT Bristol-Myers Squibb Company (NYSE: BMY) will present at Deutsche Bank's 37 th Annual Health Care Conference on Monday, May 7, 2012 in Boston. Francis Cuss, senior vice president, Research, will make a formal ... Zacks Gives Neutral Rating to Bristol Myers Squibb (BMY)Junction Report Bristol-Myers Squibb confirms it's a target of bribery probeFiercePharma 2 'Big Pharma' Stocks To Buy Instead Of Bristol-Myers SquibbSeeking Alpha los 16 artículos informativos »

Otsuka Wins Appeal Ruling Upholding Abilify Drug Patent BusinessWeek (4578)'s pharmaceutical unit and partner Bristol-Myers Squibb Co. (BMY) (BMY) won an appeals court ruling that will help ward off generic-drug competition to their schizophrenia drug Abilify until April 2015. The US Court of Appeals for the Federal ... y más »

Our Take: Mead Johnson: A Formula for Success by Mumbai News The Mumbai Times Bristol-Myers Squibb Co (NYSE:BMY) shares were trading at $33.37 while reporting down 0.39% from yesterdays close. The 17 analysts offering 12-month price forecasts for Bristol-Myers Squibb Co have a median target of 34.00, with a high estimate of ... y más »

Insiders Sold These Stocks on May-18 Fyxnews Bristol-Myers Squibb Company (NYSE:BMY): Cornelius James M (Director) sold 5000 shares at a price of $33.00. Bristol-Myers Squibb Company is a global biopharmaceutical Company, which is engaged in the discovery, development, licensing, manufacturing, ... y más »

3 Meaningfully Undervalued Healthcare Stocks Seeking Alpha As attractive as Bristol Myers (BMY) and Johnson & Johnson (JNJ) are from a risk-mitigation standpoint, Emergent Health Corp (EMGE.PK) is likely to generate higher returns. Its winning combination of attractive lines in regenerative medicine, ...

Ex-BMS exec finishes book, and sentence, in conviction FiercePharma A former Bristol-Myers Squibb ($BMY) executive has completed his sentence. In fact, he has completed quite a few sentences as part of an unusual punishment for his conviction for lying to regulators during negotiations over a generic version of ... y más »

RDY Adds to Generic Portfolio Zacks.com Last week, Dr. Reddy's announced the US launch of a generic version of Bristol-Myers Squibb & Co.'s (BMY - Analyst Report) blood thinner, Plavix. The FDA approved the ANDA for 75 mg and 300 mg formulations of the generic version of the drug.

Teva's New CEO: A Positive Catalyst Going Forward Seeking Alpha Analysts and investors got excited when Teva announced the hiring of Levin, hopeful his "Big Pharma" background and especially his recent success at Bristol-Myers Squibb (BMY) would help shake Teva out of its doldrums.

India Share Rule, Bristol-Myers Subpoena, RBS: Compliance BusinessWeek Bristol-Myers Squibb Co. (BMY) (BMY), maker of the blood thinner Plavix, said it received a US Securities and Exchange Commission subpoena last month seeking information on its ?sales and marketing practices in various countries. y más »

Bloomberg

Buzz: Big Pharma suitors line up for a look at Amylin's books FierceBiotech Amylin--while maintaining a strict no comment policy ever since initial reports appeared the Bristol-Myers Squibb ($BMY) had made an offer--has scored on both points with a Bloomberg report out this morning assessing the line of potential bidders ... Amylin Goes A Little Wizard Of Oz On ShareholdersSeeking Alpha Big-name pharmas peer at Amylin's books to prep for bidsFiercePharma los 17 artículos informativos »

Generic Launches Continue at Mylan - Analyst Blog NASDAQ Plavix, sold by Bristol-Myers Squibb Co. ( BMY ) and Sanofi ( SNY ), is approved for patients who have had a heart attack or stroke recently, or suffer from a partial or total blockage of an artery (peripheral artery disease). According to IMS Health, ...

The Zacks Analyst Blog Highlights: Gilead Sciences, Abbott Labs, Alliance Data ... Zacks.com Stocks recently featured in the blog include Gilead Sciences (GILD - Analyst Report), Abbott Labs (ABT - Analyst Report), Alliance Data Systems Corporation (ADS - Snapshot Report), Blue Nile (NILE - Snapshot Report) and Bristol-Myers Squibb (BMY ... y más »

Review:Pfizer (NYSE:PFE) Bankrupt Quigley Unit Still Seeks to Reorganize- PFE ... The Mumbai Times Bristol-Myers Squibb Co (NYSE:BMY) shares were trading at $33.19 while reporting up 1.16% from yesterdays close. The 15 analysts offering 12-month price forecasts for Bristol-Myers Squibb Co have a median target of 34.00, with a high estimate of 40.00 ... y más »

RDY Adds to Generic Portfolio - Analyst Blog NASDAQ Last week, Dr. Reddy's announced the US launch of a generic version of Bristol-Myers Squibb & Co. 's ( BMY ) blood thinner, Plavix. The FDA approved the ANDA for 75 mg and 300 mg formulations of the generic version of the drug. y más »

Pfizer (NYSE:PFE) Can Cure Rare and Deadly Child Cancers ? MRK, NVS, BMY, JNJ ... eStocksDaily Other healthcare stocks with bullish trend include Bristol Myers Squibb Co. (NYSE:BMY) up 0.37% to $32.87, Johnson & Johnson (NYSE:JNJ) up 0.24% to $63.70 and Gilead Sciences, Inc. (NASDAQ:GILD) up 0.26% to $50.23, whereas with bearish trend include ... Pfizer Inc. (NYSE:PFE) Antibiotic Zithromax Carries Small Risk Factor Of ...U.S. Election News los 3 artículos informativos »

Bristol-Myers Squibb to Present at Bank of America Merrill Lynch Health Care ... EON: Enhanced Online News (press release) NEW YORK--(EON: Enhanced Online News)--Bristol-Myers Squibb Company (NYSE: BMY) will present at Bank of America Merrill Lynch Health Care Conference on Thursday, May 17, 2012 in Las Vegas. Doug Manion, senior vice president, Development, Neuroscience, ...